Regencell Bioscience Holdings Ltd(RGC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 5 at 4:18 PM ET (Korea 11/6 06:18)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.02 | Insider Own | 88.68% | Shs Outstand | 495.9M | Perf Week | -23.18% |
| Market Cap | 2.61B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 56.1M | Perf Month | -25.88% |
| Enterprise Value | 2.60B | PEG | - | EPS next Q | - | Inst Own | 0.28% | Short Float | 0.78% | Perf Quarter | -2.59% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | 64.45% | Short Ratio | 1.8 | Perf Half Y | -83.25% |
| Sales | 0.00B | P/B | 195.77 | EPS next 5Y | - | ROA | -114.25% | Short Interest | 0.44M | Perf YTD | -74.9% |
| Book/sh | 0.03 | P/C | 184.17 | EPS past 3/5Y | -25.82% -53.29% | ROE | -128.52% | 52W High | -92.36% ($69.00) | Perf Year | -59.77% |
| Cash/sh | 0.03 | P/FCF | - | Sales past 3/5Y | - | ROIC | -87.27% | 52W Low | 16.85% ($4.51) | Perf 3Y | 1327.37% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -227.78% | Gross Margin | - | Volatility(W/M) | 12.28% 15.82% | Perf 5Y | 886.99% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.96 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.77 | EPS Q/Q | -268.57% | Profit Margin | - | RSI (14) | 34.25 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.77 | Sales Q/Q | - | SMA20 | -32.81% ($7.84) | Beta | 1.69 | Target Price | - |
| Payout | - | Debt/Eq | 0.02 | Earnings | - | SMA50 | -23.15% ($6.86) | Rel Volume | 0.73 | Prev Close | $5.42 |
| Employees | 10 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -68.52% ($16.74) | Avg Volume(3M) | 0.24M | Price | $5.27 |
| IPO | 2021/7/16 | Option/Short | Yes/Yes | Trades | 1033 | Volume | 179,489 | Change | -2.77% |
A Hong Kong-based biotech company that is in the early stages of researching treatment candidates for neurodevelopmental disorders such as ADHD (Attention Deficit Hyperactivity Disorder), built on a foundation of traditional herbal medicine.
Over the past 1 year, on the lower side
92% below its 1-year high.
Traded less than usual. That is 73% of its average volume.
RGC has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +887.0%. The S&P 500 did +56% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #20 of 83 in the industry
Based on market cap of $3B.
BHC#19 Bausch Health Companies Inc $3B PER - RGC#20 Regencell Bioscience Holdings Ltd $3B PER - 
HCM#21 HUTCHMED (China) Limited ADR $2B PER 139.6 
XERS#22 Xeris Biopharma Holdings Inc $2B PER - 
PRGO#23 Perrigo Company plc $2B PER - 
FAQ
What kind of company is RGC?
RGC belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of RGC?
The market cap of RGC is approximately $2.6B, ranking 1,834 within its sector.
What is the 52-week high and low for RGC?
RGC has recorded a 52-week high of $69.00 and a low of $4.51.
